Literature DB >> 21783284

Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents.

Alaa A-M Abdel-Aziz1, Adel S El-Azab, Sabry M Attia, Abdulrahman M Al-Obaid, Mohamed A Al-Omar, Hussein I El-Subbagh.   

Abstract

Certain new halogenated cyclic-imides related to N-substituted phthalimide moiety were synthesized. Spacers of one or two carbon atom distances were inserted to connect the N-terminus of the cyclic-imide nuclei to the used heteroaryl groups to evaluate the effect of such alteration on biological activity. The synthesized compounds were subjected to hypoglycaemic and anti-hyperlipidemic evaluation. Some of the tested compounds proved to be more potent than the reference drugs glibenclamide and clofibrate. Compound 5e remarkably reduced serum glucose level by 55%; while 5c, 5e, 7d and 8e reduced total serum cholesterol by 58, 56, 54 and 53%, respectively. Those new cyclic-imides could be considered as useful template for future development to obtain more potent hypoglycaemic and anti-hyperlipidemic agents.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21783284     DOI: 10.1016/j.ejmech.2011.07.002

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Phthalimido-thiazole as privileged scaffold: activity against immature and adult worms of Schistosoma mansoni.

Authors:  Sheilla Andrade de Oliveira; Miria de Oliveira Barbosa; Carlos André Laranjeira Miranda Filho; Arsênio Rodrigues Oliveira; Fabiano Amaro de Sousa; Edna de Farias Santiago; Gevanio Bezerra de Oliveira Filho; Paulo André Teixeira de Moraes Gomes; Juliana Maria da Conceição; Fábio André Brayner; Luiz Carlos Alves; Ana Cristina Lima Leite
Journal:  Parasitol Res       Date:  2018-05-07       Impact factor: 2.289

Review 2.  Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Authors:  Godwin Akpeko Dziwornu; Henrietta Dede Attram; Samuel Gachuhi; Kelly Chibale
Journal:  RSC Med Chem       Date:  2020-04-06

3.  2,6-Bis[(S)-1-phenyl-eth-yl]-1H,5H-pyrrolo-[3,4-f]isoindole-1,3,5,7(2H,6H)-tetrone.

Authors:  Alaa A-M Abdel-Aziz; Adel S El-Azab; Amer M Alanazi; Seik Weng Ng; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-02-29

4.  4-[(1,3-Dioxoisoindolin-2-yl)meth-yl]benzene-sulfonamide.

Authors:  Joel T Mague; Alaa A-M Abdel-Aziz; Adel S El-Azab; Magda A El-Sherbeny
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-12

5.  Synthesis, anti-inflammatory, cytotoxic, and COX-1/2 inhibitory activities of cyclic imides bearing 3-benzenesulfonamide, oxime, and β-phenylalanine scaffolds: a molecular docking study.

Authors:  Alaa A-M Abdel-Aziz; Adel S El-Azab; Nawaf A AlSaif; Mohammed M Alanazi; Manal A El-Gendy; Ahmad J Obaidullah; Hamad M Alkahtani; Abdulrahman A Almehizia; Ibrahim A Al-Suwaidan
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

6.  Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists.

Authors:  Mohamed Ayman El-Zahabi; Faida H Bamanie; Salah Ghareeb; Heba K Alshaeri; Moudi M Alasmari; Mohamed Moustafa; Zohair Al-Marzooki; Mohamed F Zayed
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.